Takeda opens new cell therapy manufacturing facility

By The Science Advisory Board staff writers

September 15, 2020 -- Takeda Pharmaceuticals said it has opened a new 24,000-sq-ft research and development (R&D) cell therapy manufacturing facility at its R&D headquarters in Boston.

The company said that the new facility will provide end-to-end R&D capabilities and accelerate its efforts to develop next-generation cell therapies. These initiatives are initially focused on oncology, but there's potential to expand into other therapeutic areas, Takeda said.

Novavax licenses COVID-19 vaccine to Takeda in Japan
Novavax and Takeda Pharmaceutical have formed a partnership for the development, manufacturing, and commercialization in Japan of NVX-CoV2373, Novavax's...
R&D Alliance begin I-Spy COVID trial
A collaborative research effort that includes the U.S. government and leading pharmaceutical companies has launched a clinical trial to investigate a...
Takeda, Twist partner on biologics discovery
Twist Bioscience and Takeda Pharmaceutical have formed a partnership for access to Twist's proprietary phage display libraries for the discovery of antibodies...
Carmine, Takeda use extracellular vesicles for rare disease gene therapies
Carmine Therapeutics has signed a research collaboration agreement with Takeda Pharmaceutical to develop gene therapies for rare diseases.
Egle, Takeda collaborate on anti-Treg immunotherapies
Egle Therapeutics has formed a strategic research alliance with Takeda Pharmaceutical to validate novel regulatory T-cells (Treg) targets, against which...

Copyright © 2020 scienceboard.net


Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Email
Conferences
ESMO Virtual Congress 2020
September 14-29
Online
2020 ACCP Annual Meeting
September 20-22
Online
BioProcess International West
September 21-25
Online
BioProcess International
September 21-25
Online
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter